The BCL-2 biomarker in the era of molecular diagnosis of diffuse large B-cell lymphoma

References

• Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce C M. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985; 229: 1390–1393
   PubMed Web of Science ®Google Scholar
• Brien G, Trescol-Biemont M C, Bonnefoy-Berard N. Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis. Oncogene advance online publication 12 March 2007
   Google Scholar
• Gascoyne R D, Adomat S A, Krajewski S, Krajewska M, Horsman D E, Tolcher A W, O'Reilly S E, Hoskins P, Coldman A J, Reed J C, Connors J M. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90: 244–251
   PubMed Web of Science ®Google Scholar
• Wilson W H, Grossbard M L, Pittaluga S, Cole D, Pearson D, Drbohlav N, Steinberg S M, Little R F, Janik J, Gutierrez M, Raffeld M, Staudt L, Cheson B D, Longo D L, Harris N, Jaffe E S, Chabner B A, Wittes R, Balis F. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 2002; 99: 2685–2693
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Wilson W H, Pittaluga S, O'Connor P, Hegde U, Drbohlav N, Janik J, Little R, Steinberg S, Cheson B, Staudt L, Raffeld M, Chabner B, Jaffe E S. Rituximab may overcome BCL-2 associated chemotherapy resistance in untreated diffuse large B-cell lymphoma. Proc Am Soc Hematol 2001; 98: 343a
   Google Scholar
• Mounier N, Briere J, Gisselbrecht C, Emile J F, Lederlin P, Sebban C, Berger F, Bosly A, Morel P, Tilly H, Bouabdallah R, Reyes F, Gaulard P, Coiffier B. Rituximab plus CHOP (R-CHOP) overcomes bcl-2—associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279–4284
   PubMed Web of Science ®Google Scholar
• Alizadeh A A, Eisen M B, Davis R E, Ma C, Lossos I S, Rosenwald A, Boldrick J C, Sabet H, Tran T, Yu X, Powell J I, Yang L, Marti G E, Moore T, Hudson J, Jr, Lu L, Lewis D B, Tibshirani R, Sherlock G, Chan W C, Greiner T C, Weisenburger D D, Armitage J O, Warnke R, Levy R, Wilson W, Grever M R, Byrd J C, Botstein D, Brown P O, Staudt L M. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan W C, Connors J M, Campo E, Fisher R I, Gascoyne R D, Muller-Hermelink H K, Smeland E B, Giltnane J M, Hurt E M, Zhao H, Averett L, Yang L, Wilson W H, Jaffe E S, Simon R, Klausner R D, Powell J, Duffey P L, Longo D L, Greiner T C, Weisenburger D D, Sanger W G, Dave B J, Lynch J C, Vose J, Armitage J O, Montserrat E, Lopez-Guillermo A, Grogan T M, Miller T P, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt L M, Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne R D, Chan W C, Zhao T, Haioun C, Greiner T C, Weisenburger D D, Lynch J C, Vose J, Armitage J O, Smeland E B, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, Lopez-Guillermo A, Ott G, Muller-Hermelink H K, Connors J M, Braziel R, Grogan T M, Fisher R I, Miller T P, LeBlanc M, Chiorazzi M, Zhao H, Yang L, Powell J, Wilson W H, Jaffe E S, Simon R, Klausner M D, Staudt L M. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851–862
   PubMed Web of Science ®Google Scholar
• Wilson W H, Grossbard M L, Pittaluga S, Cole D, Peason D, Drbohlav N, Steinberg S M, Little R F, Janik J, Gutierrez M, Raffeld M, Staudt L, Chason B D, Longo D L, Harris N, Jaffe E S, Chabner B A, Wittes R, Balis F. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 2002; 99: 2685–2693
   PubMed Web of Science ®Google Scholar
• Winter J N, Weller E A, Horning S J, Krajewska M, Variakojis D, Habermann T M, Fisher R I, Kurtin P J, Macon W R, Chhanabhai M, Felgar R E, Hsi E D, Medeiros L J, Weick J K, Reed J C, Gascoyne R D. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or RCHOP: a prospective correlative study. Blood 2006; 107: 4207–4213
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Davis E, Landgren O, Staudt L M, Wilson W H. BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?. Blood Jan 15, 2007; 109: 843–844
   PubMed Web of Science ®Google Scholar
• Davis R E, Brown K D, Siebenlist U, Staudt L M. Constitutive nuclear factor kB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194: 1861–1874
   PubMed Web of Science ®Google Scholar
• Jazirehi A R, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab {chimeric anti-CD20 monoclonal antibody} inhibits the constitutive nuclear factor-{k}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005; 65: 264–276
   PubMed Web of Science ®Google Scholar
• Li Z, Wang X, Yu R Y-L, Ding B B, Yu J J, Dai X M, Naganuma A, Stanley E R, Ye B H. BCL-6 negatively regulates expression of the NF-{k}B1 p105/p50 subunit. J Immunol 2005; 174: 205–214
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Janik J, Grant N, Shovlin M, Steinbrg S, Raffeld M, Staudt L M, Jaffe E S, Wilson W H. Primary mediastinal large B-cell lymphoma (PMBL) outcome may be significantly improved by the addition of rituximab to doseadjusted (DA)-EPOCH and obviates the need for radiation: results from a prospective study of 44 patients. Blood 2006; 108, (abs 209)
   Web of Science ®Google Scholar
• Savage K J, Monti S, Kutok J L, Cattoretti G, Neuberg D, De Leval L, Kurtin P, Dal Cin P, Ladd C, Feuerhake F, Aguier R C, Li S, Salles G, Berger F, Jing W, Pinkus G S, Habermann T, Dalla-Favera R, Harris N L, Aster J C, Golub T R, Shipp M A. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin's lymphoma. Blood 2003; 102: 3871–3879
   PubMed Web of Science ®Google Scholar